Received Jun 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | OT |
no other AE; the MMR-II vaccine to a 7 month old patient; This spontaneous report was received from a health business professional (HBP) and refers to a 7-month-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 19-MAY-2025, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), administered for prophylaxis (strength, dose, route, lot #, and expiration date were not reported) (Product administered to patient of inappropriate age). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot # and expiration date were not reported). It was reported that the patient would be travelling outside of the country next week, so the patient was back in the office on 04-JUN-2025 to receive Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB) and Pneumococcal vaccine conj 7v (CRM197) (PREVNAR). The reporter did not provide which "PREVNAR" that the patient would be receiving and did not provide any further information or patient information. No other adverse event was reported. Lot# is being requested and will be submitted if received.
Sterile diluent